Crosstalk between NRF2 and HIPK2 shapes cytoprotective responses

L. Torrente, C. Sanchez, R. Moreno, S. Chowdhry, P. Cabello, K. Isono, H. Koseki, T. Honda, J. D. Hayes, A. T. Dinkova-Kostova, L. De La Vega

Research output: Contribution to journalArticle

Abstract

Homeodomain interacting protein kinase-2 (HIPK2) is a member of the HIPK family of stress-responsive kinases that modulates cell growth, apoptosis, proliferation and development. HIPK2 has several well-characterised tumour suppressor roles, but recent studies suggest it can also contribute to tumour progression, although the underlying mechanisms are unknown. Herein, we have identified novel crosstalk between HIPK2 and the cytoprotective transcription factor NRF2. We show that HIPK2 is a direct transcriptional target of NRF2, identifying a functional NRF2 binding site in the HIPK2 gene locus and demonstrating for the first time a transcriptional mode of regulation for this kinase. In addition, HIPK2 is required for robust NRF2 responsiveness in cells and in vivo. By using both gain-of-function and loss-of-function approaches, we demonstrate that HIPK2 can elicit a cytoprotective response in cancer cells via NRF2. Our results have uncovered a new downstream effector of HIPK2, NRF2, which is frequently activated in human tumours correlating with chemoresistance and poor prognosis. Furthermore, our results suggest that modulation of either HIPK2 levels or activity could be exploited to impair NRF2-mediated signalling in cancer cells, and thus sensitise them to chemotherapeutic drugs.

Original languageEnglish (US)
Pages (from-to)6204-6212
Number of pages9
JournalOncogene
Volume36
Issue number44
DOIs
StatePublished - Nov 2 2017
Externally publishedYes

Fingerprint

Homeodomain Proteins
Protein Kinases
Neoplasms
Phosphotransferases
Transcription Factors
Binding Sites
Apoptosis

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Torrente, L., Sanchez, C., Moreno, R., Chowdhry, S., Cabello, P., Isono, K., ... De La Vega, L. (2017). Crosstalk between NRF2 and HIPK2 shapes cytoprotective responses. Oncogene, 36(44), 6204-6212. https://doi.org/10.1038/onc.2017.221

Crosstalk between NRF2 and HIPK2 shapes cytoprotective responses. / Torrente, L.; Sanchez, C.; Moreno, R.; Chowdhry, S.; Cabello, P.; Isono, K.; Koseki, H.; Honda, T.; Hayes, J. D.; Dinkova-Kostova, A. T.; De La Vega, L.

In: Oncogene, Vol. 36, No. 44, 02.11.2017, p. 6204-6212.

Research output: Contribution to journalArticle

Torrente, L, Sanchez, C, Moreno, R, Chowdhry, S, Cabello, P, Isono, K, Koseki, H, Honda, T, Hayes, JD, Dinkova-Kostova, AT & De La Vega, L 2017, 'Crosstalk between NRF2 and HIPK2 shapes cytoprotective responses', Oncogene, vol. 36, no. 44, pp. 6204-6212. https://doi.org/10.1038/onc.2017.221
Torrente L, Sanchez C, Moreno R, Chowdhry S, Cabello P, Isono K et al. Crosstalk between NRF2 and HIPK2 shapes cytoprotective responses. Oncogene. 2017 Nov 2;36(44):6204-6212. https://doi.org/10.1038/onc.2017.221
Torrente, L. ; Sanchez, C. ; Moreno, R. ; Chowdhry, S. ; Cabello, P. ; Isono, K. ; Koseki, H. ; Honda, T. ; Hayes, J. D. ; Dinkova-Kostova, A. T. ; De La Vega, L. / Crosstalk between NRF2 and HIPK2 shapes cytoprotective responses. In: Oncogene. 2017 ; Vol. 36, No. 44. pp. 6204-6212.
@article{f7735fb834f94cd7b9beb254c1883ed4,
title = "Crosstalk between NRF2 and HIPK2 shapes cytoprotective responses",
abstract = "Homeodomain interacting protein kinase-2 (HIPK2) is a member of the HIPK family of stress-responsive kinases that modulates cell growth, apoptosis, proliferation and development. HIPK2 has several well-characterised tumour suppressor roles, but recent studies suggest it can also contribute to tumour progression, although the underlying mechanisms are unknown. Herein, we have identified novel crosstalk between HIPK2 and the cytoprotective transcription factor NRF2. We show that HIPK2 is a direct transcriptional target of NRF2, identifying a functional NRF2 binding site in the HIPK2 gene locus and demonstrating for the first time a transcriptional mode of regulation for this kinase. In addition, HIPK2 is required for robust NRF2 responsiveness in cells and in vivo. By using both gain-of-function and loss-of-function approaches, we demonstrate that HIPK2 can elicit a cytoprotective response in cancer cells via NRF2. Our results have uncovered a new downstream effector of HIPK2, NRF2, which is frequently activated in human tumours correlating with chemoresistance and poor prognosis. Furthermore, our results suggest that modulation of either HIPK2 levels or activity could be exploited to impair NRF2-mediated signalling in cancer cells, and thus sensitise them to chemotherapeutic drugs.",
author = "L. Torrente and C. Sanchez and R. Moreno and S. Chowdhry and P. Cabello and K. Isono and H. Koseki and T. Honda and Hayes, {J. D.} and Dinkova-Kostova, {A. T.} and {De La Vega}, L.",
year = "2017",
month = "11",
day = "2",
doi = "10.1038/onc.2017.221",
language = "English (US)",
volume = "36",
pages = "6204--6212",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "44",

}

TY - JOUR

T1 - Crosstalk between NRF2 and HIPK2 shapes cytoprotective responses

AU - Torrente, L.

AU - Sanchez, C.

AU - Moreno, R.

AU - Chowdhry, S.

AU - Cabello, P.

AU - Isono, K.

AU - Koseki, H.

AU - Honda, T.

AU - Hayes, J. D.

AU - Dinkova-Kostova, A. T.

AU - De La Vega, L.

PY - 2017/11/2

Y1 - 2017/11/2

N2 - Homeodomain interacting protein kinase-2 (HIPK2) is a member of the HIPK family of stress-responsive kinases that modulates cell growth, apoptosis, proliferation and development. HIPK2 has several well-characterised tumour suppressor roles, but recent studies suggest it can also contribute to tumour progression, although the underlying mechanisms are unknown. Herein, we have identified novel crosstalk between HIPK2 and the cytoprotective transcription factor NRF2. We show that HIPK2 is a direct transcriptional target of NRF2, identifying a functional NRF2 binding site in the HIPK2 gene locus and demonstrating for the first time a transcriptional mode of regulation for this kinase. In addition, HIPK2 is required for robust NRF2 responsiveness in cells and in vivo. By using both gain-of-function and loss-of-function approaches, we demonstrate that HIPK2 can elicit a cytoprotective response in cancer cells via NRF2. Our results have uncovered a new downstream effector of HIPK2, NRF2, which is frequently activated in human tumours correlating with chemoresistance and poor prognosis. Furthermore, our results suggest that modulation of either HIPK2 levels or activity could be exploited to impair NRF2-mediated signalling in cancer cells, and thus sensitise them to chemotherapeutic drugs.

AB - Homeodomain interacting protein kinase-2 (HIPK2) is a member of the HIPK family of stress-responsive kinases that modulates cell growth, apoptosis, proliferation and development. HIPK2 has several well-characterised tumour suppressor roles, but recent studies suggest it can also contribute to tumour progression, although the underlying mechanisms are unknown. Herein, we have identified novel crosstalk between HIPK2 and the cytoprotective transcription factor NRF2. We show that HIPK2 is a direct transcriptional target of NRF2, identifying a functional NRF2 binding site in the HIPK2 gene locus and demonstrating for the first time a transcriptional mode of regulation for this kinase. In addition, HIPK2 is required for robust NRF2 responsiveness in cells and in vivo. By using both gain-of-function and loss-of-function approaches, we demonstrate that HIPK2 can elicit a cytoprotective response in cancer cells via NRF2. Our results have uncovered a new downstream effector of HIPK2, NRF2, which is frequently activated in human tumours correlating with chemoresistance and poor prognosis. Furthermore, our results suggest that modulation of either HIPK2 levels or activity could be exploited to impair NRF2-mediated signalling in cancer cells, and thus sensitise them to chemotherapeutic drugs.

UR - http://www.scopus.com/inward/record.url?scp=85032962106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032962106&partnerID=8YFLogxK

U2 - 10.1038/onc.2017.221

DO - 10.1038/onc.2017.221

M3 - Article

C2 - 28692050

AN - SCOPUS:85032962106

VL - 36

SP - 6204

EP - 6212

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 44

ER -